Effectiveness of Short-term Dynamic Psychotherapy versus Sertraline in Treatment of Social Phobia by ندرمحمدی مقدم, مهریار et al.
Iran J Psychiatry Behav Sci. 2015 June; 9(2):e228. DOI: 10.17795/ijpbs228
Published online 2015 June 8. Original Article
Effectiveness of Short-term Dynamic Psychotherapy versus Sertraline in 
Treatment of Social Phobia 
Mehryar Nader-Mohammadi Moghadam 
1
; Mohammad-Kazem Atef-Vahid 
1,*
; Ali-Asghar 
Asgharnejad-Farid 
1
; Amir Shabani 
1
; Fahimeh Lavasni 
1
1Tehran Institute of Psychiatry, Tehran University of Medical Sciences Tehran, IR Iran*Corresponding author: Mohammad-Kazem Atef-Vahid, Tehran Institute of Psychiatry, Tehran University of Medical Sciences, Tehran, IR Iran. Tel: +98-2166506862, Fax: +98-2166506862, 
E-mail: kazemv@yahoo.com
Received: October 25, 2014; Revised: November 22, 2014; Accepted: February 7, 2015
Background: A few studies on short-term psychodynamic approach have been conducted on social phobia.
Objectives: In this study, the effectiveness of short-term psychodynamic psychotherapy on the treatment of social phobia has been 
compared to the effectiveness of sertraline and waiting list.
Materials and Methods: In this randomized-controlled trial study, 13 male students were treated with short-term dynamic psychotherapy 
(McCullough method) lasting 25 sessions, 11 students received sertraline for 12 weeks, and 14 students, as the waiting list, received no 
intervention for 8 weeks. Participants completed the Social Phobia Inventory (SPIN) as primary efficacy variable 4 times, and were rated 
with Clinical Global Impression scale (CGI) and Global Assessment of Functioning (GAF) as secondary efficacy variables. The data were 
analyzed with analysis of variance (ANOVA), analysis of covariance (ANCOVA), general linear model repeated measures analysis of variance 
and Fisher exact test.
Results: ANCOVA showed significant differences between groups based on SPIN scores (F = 23.51, Sig. = 0.001) and Bonferroni test, as post 
hoc compression, showed means of both short-term dynamic therapy and sertraline therapy groups were significantly different from 
waiting list mean (STDP-WL: x¯dif = 15.76, Sig. = 0.001), (MED-WL: x¯ = 15.91, Sig. = 0.001). Mean of SPIN scores was not significantly different 
between short-term dynamic psychotherapy and pharmacotherapy groups. In both treatment groups, means of SPIN scores significantly 
decreased in posttest, but not in waiting. These results repeated with GAF and CGI scores.
Conclusions: The results indicated that short-term dynamic psychotherapy sertraline are effective in decreasing social phobia symptoms 
and were superior to control group.
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1. Background
Social phobia is one of the most prevalent psychiatric 
disorders (1-5) and usually begins at young ages, between 
14 and 34 years (2, 6-9). Studies have shown that on aver-
age people with severe symptoms have suffered from this 
disorder for 20 years (10, 11). Social phobia is a durable 
disorder even after years of treatment (12, 13). More than 
80% of people who suffer from social phobia have anoth-
er comorbid disorder (14, 15). This disorder causes more 
pervasive problems than other anxiety disorders (15-18). 
Retrospective and prospective epidemiological stud-
ies suggest that social phobia can create confusion and 
deep problems in life, including problems in school and 
college achievement (2, 11, 18) and can disrupt job perfor-
mance (15, 16) and social development (2, 15, 16). Studies 
have shown that regardless of the cost of comorbidities, 
the annual per capita costs of social phobia is $ 6100 (19). 
A wide range of therapies has been introduced for the 
treatment of social phobia (20). Pharmacotherapy (21), 
psycho-education, cognitive-behavioral therapy (22), be-
havior therapy (23) and psycho-analytic psychotherapy 
are common treatment methods for social phobia (24).
Effectiveness of different types of drugs has been stud-
ied in the treatment of social phobia (21). Selective sero-
tonin reuptake inhibitors (SSRI) are first-line treatments 
of social phobia (Effect size of 0.65 with 95% confidence 
interval, 0.81 to 0.50) (20). Effectiveness of sertraline in 
several studies has been confirmed too (25-29).
Some studies have shown that social phobia or social 
anxiety disorder may respond to cognitive and behav-
ioral therapy very slowly (30) and response to treatment 
with Cognitive behavioral therapy (CBT) for the treat-
ment of social phobia-about 50%-is not satisfactory (31, 
32). Also it seems that relaxation training alone is ineffec-
tive for the treatment of social phobia (33).
Although the effectiveness of psychodynamic psycho-
therapy on the treatment of several disorders has been 
studied, Fonagy (2005) stated “there is no controlled 
research study for two common problems; anxiety and 
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social phobia” (34). Blanco and colleagues’ study (2003) 
also confirmed the absence of empirical studies on the 
effectiveness of psychodynamic psychotherapy on the 
treatment of social phobia (20).
McCullough’s approach, called Affect Phobia Treatment 
(APT), is one of the well-known short-term dynamic psy-
chotherapies (35). McCullough has developed a specific 
manual for her therapeutic approach. According to her, 
facilitating the occurrence of emotions and leaving de-
fense mechanisms ultimately leads to the relief of symp-
toms of the disorder. APT focuses on resolving emotional 
conflicts and the underlying psychodynamic framework. 
Three techniques are used in APT: affect restructuring, 
defense restructuring, and self/other restructuring (36). 
Affect restructuring consists of two parts. First, the thera-
pist helps the patients to slowly become more related 
with their own internal emotional experiences. Second, 
they learn how to express emotions in interpersonal re-
lationships. Defense restructuring consists of two parts. 
First of all, the therapist helps the patients to recognize 
their defenses against emotional problems. Then, the 
patients become familiar with the advantages and disad-
vantages of using these defenses and gradually give them 
up. Restructuring the sense of self and others consists of 
two parts. First, the individual’s relationship with oneself 
is guided toward creating more positive feelings. Second, 
person’s communications with others are guided to cre-
ate satisfactory and good mutual relations (37). 
APT is effective in patients with cluster C personality dis-
orders (38, 39). Dehghani’s study in Iran has shown that 
this treatment is effective in love failure (40), but the ef-
fectiveness of this method has not been evaluated in the 
treatment of anxiety disorders (41).
2. Objectives
With regard to inadequate information about effective-
ness of psychodynamic approaches in treating social 
phobia and relatively low impact of other treatment 
approaches, also considering the high prevalence and 
extensive damage of social phobia, the aim of this study 
was to compare the effectiveness of McCullough’s short-
term dynamic psychotherapy versus medication (sertra-
line) in treating social phobia.
3. Materials and Methods
This study used a quasi-experimental design with pre-
test-posttest repeated measures in multiple groups. The 
data were gathered from 22 December 2011 to 19 June 
2012. The sample consisted of 45 male students of Teh-
ran University who met the criteria for social phobia. The 
inclusion criteria were as follows: SPIN score ≥ 24, age 
between 18 to 50 years, and meeting the DSM-IV-TR crite-
ria for social phobia based on SCID. The exclusion criteria 
were as follows: being psychotic, or obsessive-compul-
sive; having bipolar, or organic brain disorders; drug and 
alcohol dependency; having impulse control disorders, 
cluster A and B personality disorders, active disorder on 
axis III, a history of suicidal thoughts and actions, a his-
tory of violent behavior; being on psychotropic medica-
tions or receiving psychotherapy for the treatment of 
social phobia during the last 6 months, or experiencing 
the symptoms of social phobia as part of other psychiat-
ric disorders. The participants were randomly assigned 
into 3 groups: 1- psychotherapy (STDP), 2- medical therapy 
(MED) and 3- waiting list (WL).
The inclusion and exclusion criteria were evaluated by 
the demographic characteristic questionnaire and the 
Structural Clinical Interview for DSM-IV (SCID-I, II) (42). 
The Social Phobia Inventory (SPIN) (43) was used for the 
primary effectiveness variable, Global Clinical Impres-
sion-Severity and Improvement (CGI-S, CGI-I) (44) and 
Global Assessment of Functioning (GAF) (45) were used 
for the secondary effectiveness variables. All instruments 
have acceptable validity and reliability (SPIN: r > 0.80, 
CGI: r > 0.65, GAF: r > 0.69, and SCID: r > 0.90). Diagnostic 
interviews were conducted by a psychiatrist.
Patients in the STDP group received 21 individual psy-
chotherapy sessions, twice per week, in addition to 4 ini-
tial and posttest evaluation sessions. The therapy sessions 
were conducted using McCullough’s manual. Members 
of the MED group received pharmacotherapy (sertraline) 
for 12 weeks. Patients in the WL group received no inter-
vention. However, after the waiting period, they received 
preferred treatment services. Each group was evaluated 4 
times during the study.
Statistical analyses were performed using SPSS version 
16. Differences between groups in pretest and posttest 
scores of SPIN, GAF, CGI-I, CGI-S were assessed using analy-
sis of variance, analysis of covariance, and Bonferroni as 
Post hoc test. Differences created during the T1, T2, T3, and 
T4 evaluations were analyzed using General Linear Model 
repeated measures analysis of variance.
Remission was defined as CGI-I = 1 and SPIN < 16. Response 
to treatment was defined as CGI-S ≤ 2 and 50% reduction 
in SPIN scores at posttest (T4) compared to the baseline (T1) 
scores (46). Differences between the groups in the percent-
ages of the patients showing remission and responding to 
treatment were determined using Fisher exact test. The ef-
fect size was calculated using pretests and posttest mean 
scores and was evaluated by Cohen’s scale (Figure 1).
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Figure 1. SPIN Scores in the Assessments of T1, T2, T3, T4
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4. Results
The demographic characteristics of the study sample 
are presented in Table 1. No significant differences were 
observed among the groups regarding the demographic 
variables, history of psychiatric problems, and drug use. 
Means and standard deviations of SPIN, GAF, and CGI-S 
scores at pretest and posttest evaluations for each group 
are presented in Table 2. There were no significant differ-
ences between the groups in terms of the pretest mean 
scores of SPIN (F = 0.737, P < 0.485), CGI-S (F = 1.35, P < 
0.269), and GAF (F = 2.571, P < 0.88).
ANCOVA showed significant differences between the 
three groups regarding the posttest scores of SPIN (F = 
23.51, P < 0.001). Pretest scores were considered as covari-
ate. Bonferroni revealed that the posttest scores of STDP 
and MED were significantly different from WL scores 
(STDP-WL: x¯dif  = -15.76, P < 0.001, MED-WL: x¯dif  = -15.91, P 
< 0.001). However, no significant difference was noted be-
tween the STDP and MED groups (STDP-MED: x¯dif  = 0.143, 
P < 0.313). Similar findings were obtained regarding CGI-S, 
CGI-I and GAF mean scores (Table 3).
Repeated measures ANOVA revealed no significant 
differences regarding various assessments of SPIN be-
tween STDP and MED (within group effect, time group: F 
= 0.423, P = 0.658, between group effect, time group: F = 
0.219, P = 0.645). But the measures of both groups were 
significantly different from WL (within group effect, 
time group: F = 14.86, P < 0.01, between group effect, time 
group: F = 25.28, P < 0. 01).
The numbers and percentages of the patients who had 
responded to treatment and had shown remission in each 
group are presented in Table 4. There were no significant 
difference among the groups regarding the number and 
percentages of the patients who had responded to treat-
ment and showed remission. The effect sizes of interven-
tions were calculated by comparing the pretest and post-
test mean scores based on Cohen’s scale (Table 5).
Table 1. Demographic Characteristics in 3 Groups a, b
Group STDP MED WL
Education
Masters 3 (20) 5 (33) 4 (26.7)
Bachelor 12 (80) 10 (67) 11 (73.3)
Marital status
Single 15 (100) 14 (93.34) 15 (100)
Married 0 (0) 1 (6.66) 0 (0)
Employment
Employed 1 (6.66) 0 (0) 0 (0)
Unemployed 14 (93.34) 15 (100) 15 (100)
Previous psychiatric 
problems
Having 2 (13.3) 3 (20) 1 (6.7)
No 13 (86.7) 12 (80) 14 (93.3)
Age 24.26 ± 1.5 24.62 ± 2.8 24.47 ± 1.6
a  Abbreviations: MED, medication; STDP, short-term dynamic 
psychotherapy; WL, waiting list.
b  Data are presented as mean ± SD or No. (%).
Table 2. The Means and Standard Deviations of Pretest and Post-
test Scores for Each Group
Group STDP MED WL
SPIN
Pretest 35.47 ± 8.56 36.53 ± 9.13 32.93 ± 7.22
Posttest 23 ± 10.39 19.27 ± 8.86 35 ±7.22
GAF
Pretest 59.06 ± 6.94 63.46 ± 5.96 64.07 ± 6.4
Posttest 71.46 ± 6.85 70.72 ± 9.23 62.64 ± 7.76
CGI-S
Pretest 4.47 ± 0.990 3.93 ± 0.884 4.20 ± 0.775
Posttest 3.31 ± 1.43 2.73 ± 1.34 4.43 ± 0.851
a  Abbreviations: CGI-S, Clinical Global Impression-severity; GAF, Global 
Assessment of Functioning; MED, medication; SPIN, Social Phobia 
Inventory; WL, waiting list.
b  Data are presented as mean ± SD.
Table 3. Results of ANCOVA and the Post Hoc Comparisons (Bon-
ferroni) for Posttest Mean Scores on the CGI-S, CGI-I and GAF a, b
Scale CGI-S (F =11.54), 
(P < 0.001)
CGI-Ic (F = 16.08), 
(P < 0.001)
GAF (F = 19.97), 
(P < 0.011)
Group
STDP-MED 0.025 (0.98) -0.035 (0.293) 3.22 (0.510)
STDP-WL -1.56 (0.001) -1.37 (0.001) 13.75 (0.001)
MED-WL -1.58 (0.001) -1.344 (0.001) 10.52 (0.001)
a  Abbreviations: CGI-S, Clinical Global Impression-severity; CGI-I, 
Clinical Global Impression-improvement; GAF, Global Assessment 
of Functioning; MED, medication; STDP, short-term dynamic 
psychotherapy; WL, waiting list.
b  Data are presented as x¯dif  (P value).
c  CGI-I posttest scores were analyzed using ANOVA.
Table 4. Response to Treatment and Remission Rate in Interven-
tion Groups a, b
Response to 
Treatment
Fisher 
Exact Test
Remission Fisher 
Exact Test
STDP 4 (30.76) P = 0.675 2 (15.38) P = 1
MED 5(36.11) 2 (18.18)
a  Abbreviations: MED, medication; STDP, short-term dynamic 
psychotherapy.
b  Remission: CGI-I = 1 and SPIN < 16. Response to treatment: CGI-S ≤ 2 
and 50% reduction in SPIN T4 scores than baseline.
Table 5. Effect Sizes of Interventions Based on Cohen’s d a, b
Scale SPIN CGI-S GAF
Group
STDP 1.19 0.811 1.81
MED 1.94 0.895 0.79
WL 0.286 0.270 0.184
a  Abbreviations: CGI-S, Clinical Global Impression-severity; GAF, 
Global Assessment of Functioning; MED, medication; STDP, short-term 
dynamic psychotherapy; WL, waiting list.
b  Cohen’s d: 0 - 0.2, small; 0.3 – 0.5, medium; 0.6- 0.8, large; > 0.9, very 
large.
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5. Discussion
Based on the results of the study, both short-term dynamic 
psychotherapy and treatment with sertraline were effective 
in significantly reducing the symptoms of social phobia as 
compared to the waiting list. These results are consistent 
with the findings of Bogels (47), and considering general 
psychiatric symptoms are in line with Crits-Christoph (48), 
Leichsenring (49, 50), and Lewis (51) studies. Both short-
term psychodynamic and pharmacological interventions 
were almost equally effective in improving the overall func-
tioning of patients with social phobia and had advantage 
over no treatment condition. These findings are consistent 
with the findings of Knekt (52) and Blanco (20) regarding 
the positive effects of psychodynamic psychotherapy on 
the various functions. Leichsenring (49) obtained an effect 
size of 1.29 for psychodynamic psychotherapy regarding 
the improvement in the overall functioning, which is lower 
than the one we obtained in the present study (ES = 1.81).
No significant differences were found between two 
groups in the number of patients who responded to the 
treatment (P = 0.675). Response to treatment rate ob-
tained in this study (STDP: 30.76%) was smaller than the 
rates reported by Knijnik (79.3%) (53) and Bressi (60%) (54). 
There was no significant difference between two groups 
regarding remission rate (P = 1). However, the percentage 
of patients who had remission was higher in this study 
than the percentage reported by Knijnik (10.3%) (53). 
In MED group, the percentages of patients who had 
remission and responded to treatment were 18.18% and 
36.11%, respectively, which were lower than the findings of 
Van Ameringen study (25).
The obtained within group effect size based on Social 
Phobia Inventory for the psychodynamic psychothera-
py (ES = 1.19) was almost similar to the ones reported by 
Leichsenring (ES = 1.39) (49) and Abbass (ES = 1.35) (55). 
However, the effect size for the psychotherapy group was 
lower than the one for the medication group (ES = 1.94). 
This result was consistent with the findings reported by 
Anderson (56) and Svartberg (38). In the medical inter-
vention group, the obtained effect size (0.895) based on 
CGI-S scores was greater than the ones reported in other 
studies (25, 53, 57). Effect sizes obtained for both inter-
vention groups were "very large" based on Cohen’s scale. 
Means of repeated evaluations in both medication and 
psychotherapy groups were not significantly different 
from each other (F = 0.219, P = 0.645), but both were signif-
icantly different from the waiting list (F = 14.86, P < 001). 
Apparently, patients who received this therapy (APT) 
by becoming familiar and controlling their own defense 
mechanisms (such as pseudo altruism, projection, and 
idealization) get opportunity to better understand their 
feelings (mainly their fears) (37, 38) toward themselves 
and others and were able to show more easily their emo-
tions. It also seems that this treatment modified and im-
proved patients’ expectations and behaviors (37). These 
changes led to a reduction in symptoms of social phobia. 
Overall, according to the results of this study, short-term 
psychodynamic psychotherapy is as effective as medica-
tion in alleviating the symptoms of social phobia and 
both interventions have large effect sizes in treatment of 
social phobia disorder. Thus, APT method of short-term 
psychodynamic psychotherapy can be considered as an 
effective method of treatment for social phobia.
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